Access to essential anticancer medicines for children and adolescents in Europe

Autor: Vassal, G., Kozhaeva, O., Griskjane, S., Arnold, F., Nysom, K., Basset, L., Kameric, L., Kienesberger, A., Kamal, S., Cherny, N., Bricalli, G., Latino, N., Kearns, P.

Publikováno v: In Annals of Oncology April 2021 32(4):560-568

REMIT: Reirradiation of Diffuse Midline Glioma Patients -A Nordic Society of Paediatric Haematology and Oncology Feasibility Study.

Autor: Østergaard DE; Section of Radiotherapy, Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark. Electronic address: daniella.elisabet@gmail.com., Embring A; Department of Oncology, Karolinska University Hospital, Sweden; Department of Oncology-Pathology, Karolinska Institute, Sweden., Sehested A; Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark., Magelssen H; Department of Oncology, Oslo University Hospital, Oslo, Norway., Vogelius IR; Section of Radiotherapy, Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark., Kjærsgaard M; Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark., Nysom K; Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark., Mathiasen R; Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark., Lukacova S; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Maraldo MV; Section of Radiotherapy, Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Publikováno v: Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2024 Nov 06; Vol. 37, pp. 103682. Date of Electronic Publication: 2024 Nov 06.

Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.

Autor: Pearson AD; ACCELERATE, Europe, Belgium. Electronic address: andy1pearson@btinternet.com., DuBois SG; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA., Macy ME; Childrens' Hospital, CO, USA., de Rojas T; ACCELERATE, Europe, Belgium., Donoghue M; US Food and Drug Administration, Silver Springs, MD, USA., Weiner S; Children's Cancer Cause, Washington, DC, USA., Knoderer H; Loxo Oncology at Lilly, USA., Bernardi R; Genentech, A Member of the Roche Group, South San Francisco, CA USA., Buenger V; Coalition Against Childhood Cancer (CAC2), Philadelphia, USA., Canaud G; Necker Enfants Malades Hospital, Paris, France., Cantley L; Harvard Medical School, Boston, USA., Chung J; Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA., Fox E; St Jude Children's Research Hospital, TN, USA., Friend J; Kazia Therapeutics, NJ, USA., Glade-Bender J; Memorial Sloan Kettering Cancer Centre, New York, USA., Gorbatchevsky I; Celcuity Inc., Minneapolis, MN, USA., Gore L; Childrens' Hospital, CO, USA., Gupta A; The Hospital for Sick Children (SickKids), Princess Margaret Hospital Toronto, Canada., Hawkins DS; Seattle Children's Hospital, Seattle, USA., Juric D; Massachusetts General Hospital, Boston, USA., Lang LA; Rally Foundation for Childhood Cancer Research, Atlanta, GA, USA., Leach D; National Brain Tumor Society, Newton, MA, USA., Liaw D; Merck Sharp & Dohme, NJ, USA., Lesa G; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), the Netherlands., Ligas F; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), the Netherlands., Lindberg G; The EVAN Foundation, Germantown, MD, USA., Lindberg W; The EVAN Foundation, Germantown, MD, USA., Ludwinski D; Solving Kids' Cancer, New York, USA., Marshall L; The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK., Mazar A; Actuate Therapeutics Inc., For worth, TX, USA., McDonough J; The Andrew McDonough B+ Foundation, Wilmington, DE, USA., Nysom K; Righospitalet, Copenhagen, Denmark., Ours C; National Human Genome Research Institute/National Institutes of Health, MD, USA., Pappo A; St Jude Children's Research Hospital, TN, USA., Parsons DW; Texas Children's Cancer and Hematology Center, TX, USA., Rosenfeld A; AstraZeneca, Waltham, MA, USA., Scobie N; Zoe4Life, Sullens, Switzerland., Smith M; National Cancer Institute, MD, USA., Taylor D; PORT (Paediatric Oncology Reference Team), London, UK., Weigel B; University of Minnesota, Minneapolis, USA., Weinstein A; Pediatric Brain Tumor Foundation of the US, Atlanta, USA., Karres D; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), the Netherlands., Vassal G; ACCELERATE, Europe, Belgium; Gustave Roussy Cancer Centre, Paris, France.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Aug; Vol. 207, pp. 114145. Date of Electronic Publication: 2024 Jun 08.

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.

Autor: Kilburn LB; Children's National Hospital, Washington, DC, USA. lkilburn@childrensnational.org., Khuong-Quang DA; Children's Cancer Centre, Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia., Hansford JR; Michael Rice Centre for Hematology and Oncology, Women's and Children's Hospital, Adelaide, South Australia, Australia.; South Australia Health and Medical Research Institute, Adelaide, Australia; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, South Australia, Australia., Landi D; Duke University, Durham, NC, USA., van der Lugt J; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Leary SES; Cancer and Blood Disorders Center, Seattle Children's, Seattle, WA, USA., Driever PH; Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Berlin, German HIT-LOGGIC-Registry for LGG in Children and Adolescents, Berlin, Germany., Bailey S; Great North Children's Hospital and Newcastle University Centre for Cancer, Newcastle-upon-Tyne, UK., Perreault S; CHU Sainte-Justine, Université de Montréal, Montréal, Quebec, Canada., McCowage G; Sydney Children's Hospitals Network, Westmead, New South Wales, Australia., Waanders AJ; Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA., Ziegler DS; Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, Australia.; School of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia., Witt O; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.; Clinical Cooperation Unit, Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany., Baxter PA; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA., Kang HJ; Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul National University Children's Hospital, Seoul, Republic of Korea., Hassall TE; Children's Health Queensland Hospital and Health Service, South Brisbane, QLD, Australia., Han JW; Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea., Hargrave D; UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children, London, UK., Franson AT; C.S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, MI, USA., Yalon Oren M; Pediatric Hemato-Oncology, Sheba Medical Center, Ramat Gan, Israel., Toledano H; Department of Pediatric Oncology, Schneider Children's Medical Center, Petach Tikva, and Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Larouche V; Department of Pediatrics, Centre Mère-Enfant Soleil du CHU de Québec-Université Laval, Quebec City, Quebec, Canada., Kline C; Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Abdelbaki MS; Division of Hematology and Oncology, Department of Pediatrics, School of Medicine, Washington University, St. Louis, MO, USA., Jabado N; McGill University Health Centre (MUHC), Montreal Children's Hospital (MCH), Montreal, Quebec, Canada., Gottardo NG; Department of Pediatric and Adolescent Oncology and Hematology, Perth Children's Hospital, Perth, Australia, and Brain Tumor Research Program, Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia., Gerber NU; Department of Oncology, University Children's Hospital, Zurich, Switzerland., Whipple NS; Primary Children's Hospital and University of Utah, Salt Lake City, UT, USA., Segal D; NYU Langone Health, New York, NY, USA., Chi SN; Pediatric Neuro-Oncology, Department of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA., Oren L; Department of Hematology & Oncology, Rambam Healthcare Campus, Haifa, Israel., Tan EEK; Haematology/Oncology Service, KK Women's and Children's Hospital, Singapore, Singapore., Mueller S; Department of Neurology, Neurosurgery and Pediatrics, University of California, San Francisco, San Francisco, CA, USA., Cornelio I; Day One Biopharmaceuticals, Brisbane, CA, USA., McLeod L; Day One Biopharmaceuticals, Brisbane, CA, USA., Zhao X; Day One Biopharmaceuticals, Brisbane, CA, USA., Walter A; Day One Biopharmaceuticals, Brisbane, CA, USA., Da Costa D; Day One Biopharmaceuticals, Brisbane, CA, USA., Manley P; Day One Biopharmaceuticals, Brisbane, CA, USA., Blackman SC; Day One Biopharmaceuticals, Brisbane, CA, USA., Packer RJ; Division of Neurology, Brain Tumor Institute, Center for Neuroscience and Behavioral Medicine, Children's National Hospital, Washington, DC, USA., Nysom K; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

Publikováno v: Nature medicine [Nat Med] 2024 May; Vol. 30 (5), pp. 1500.

129P Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score

Autor: Kushner, B., Mora, J., Chan, G., Morgenstern, D.A., Amoroso, L., Nysom, K., Faber, J., Wingerter, A., Bear, M., San Simón, A. Rubio, During, M., Tornøe, K.

Publikováno v: In Immuno-Oncology and Technology December 2023 20 Supplement